Skip to Content


In the US, Pegloticase (pegloticase systemic) is a member of the drug class antihyperuricemic agents and is used to treat Gout.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Therapeutic Categories


Treatment of gout

Chemical Name

Tetramer α₄ of des-(1-5)-[6-threonine, 45-threonine, 290-lysine, 300-serine]uricase (EC, urate oxidase) from Sus scrofa(porcine), non acetylated, of which some of the lysine 6-amine residues are engaged in a carbamate linkage with a monomethylic e (WHO )

Foreign Names

  • Pegloticasum (Latin)
  • Pegloticase (German)
  • Pégloticase (French)
  • Pegloticasa (Spanish)

Generic Names

  • Pegloticase (OS: USAN)
  • Methoxypolyethylene glycol uricase (IS)
  • PEG-Urat oxidase (IS)
  • PEG-Uricase (IS)

Brand Names

  • Krystexxa
    Crealta, Poland; Crealta, United States; Savient, Spain


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.